Posts With Tag Cell Therapies

AstraZeneca PLC completes the acquisition of EsoBiotec for up to $1 billion, enhancing its oncology portfolio with innovative cell therapies. Learn more about this transformative deal.

Explore Pluri Inc.'s Q4 2024 financial report, highlighting key losses, R&D investments, and compliance challenges. A cautious hold recommendation is advised for investors.